Home

tenda compagno Tempo avelumab clinical trials attrice chop abbraccio

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data | Scientific Reports
Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data | Scientific Reports

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine

Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews

ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma
ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma

Cancer immunotherapies targeting the PD-1 signaling pathway | Journal of Biomedical Science | Full Text
Cancer immunotherapies targeting the PD-1 signaling pathway | Journal of Biomedical Science | Full Text

PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar
PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer - Cancer Treatment Reviews
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer - Cancer Treatment Reviews

Avelumab Maintenance Therapy Shows Favorable Results After Frontline Chemotherapy in Bladder Cancer
Avelumab Maintenance Therapy Shows Favorable Results After Frontline Chemotherapy in Bladder Cancer

Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram
Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram

Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma - Kazandjian - 2021 - The Oncologist - Wiley Online Library
Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma - Kazandjian - 2021 - The Oncologist - Wiley Online Library

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - European Urology
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - European Urology

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial - The Lancet Oncology
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial - The Lancet Oncology

Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews

PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar
PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial - The Lancet Oncology
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial - The Lancet Oncology

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial | Journal for ImmunoTherapy of Cancer
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial | Journal for ImmunoTherapy of Cancer

Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews

PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar
PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | NEJM
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | NEJM

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial - Lung Cancer
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial - Lung Cancer

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study -
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study -